JavaScript is unavailable or disabled; so you are probably going to miss out on a few things. Everything should still work, but with a little less pzazz!

The William Harvey Research Institute

Research menu


Cardiovascular disease is the number one cause of death worldwide, and in parts of London the early mortality rate from cardiovascular disease is currently one of the worst in England at 85 per 100,000 of the population, compared to 67 per 100,000 in England, and 50 per 100,000 in Europe.

Queen Mary University of London and University College London (UCL) have established a joint cardiovascular Institute to rise to the global challenge of cardiovascular disease. The endeavour between the two institutions provides system-wide support for UCLPartners' cardiovascular Academic Medical Centre, the hub of which is the new Barts Heart Centre at St Bartholemews Hospital. By combining joint strengths in discovery science, experimental medicine and population health sciences and our involvement with the Farr Institute, and Genomics England, we are driving forward diagnostic and therapeutic innovation and prevention strategies to address the extensive burden of cardiovascular disease in North Central and East London.

The excellence of our cardiovascular (CV) research has been recognised by the award of a National Institute for Health Research (NIHR) Biomedical Research Centre (£12m). This integrates cardiovascular genetics, stem-cell biology, inflammation science, pharmacology, electrophysiology, advanced CV Imaging with experimental medicine and large-scale trials to create a flow of concepts from the bench into the clinic. This is boosted by the new £25m William Harvey Heart Centre and appointment of new Chairs and Teams.

A £400m rebuild of St Bartholomew’s Hospital was completed in 2014 and is home to the merged specialist cardiovascular care services of the London Chest Hospital (Barts NHS Trust), The Heart Hospital (University College London Hospitals Trust) and The Royal Free Hospital (Royal Free London NHS Foundation Trust). This provides an exciting forum for WHRI academics and our partners above to further enhance and develop cardiovascular translational research.

  • Our research and leadership changed NICE Guidance for blood pressure and cholesterol in 2006 and 2011.
  • We created and lead the Joint UK Society’s Working Group on Renal Denervation, produced the first consensus statement and are forming the UK registry for this technology.
  • We host three Wellcome and four British Heart Foundation (BHF) Programme Grants (£4 million).
  • We have won two major EU Awards (€11m), a Medical Research Council (MRC) e-Health Centre (£4.5m joint with UCL, the School of Hygiene and Health Protection Agency)and a Grand Challenge Exploration Phase II award from the Gates Foundation.
  • The NIHR Barts Biomedical Research Centre (BRC).
  • We host multiple BHF Intermediate Basic Science and NIHR Awards.
  • Awarded BHF PhD Studentship Scheme (4 year PhD with MRes for 4 years) in 2012.
  • Awarded MRC MRes/PhDs cardiovascular and inflammation in-vivo research awarded in 2012.
  • NIHR Academic Fellows in Clinical Pharmacology and Clinical Lectureships in Cardiology, Clinical Pharmacology and Renal Medicine.


More on cardiovascular research

Return to top